Skip to search formSkip to main contentSkip to account menu

TRC102

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

methoxyamine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.
2518Background: TRC102 inhibits BER by binding to abasic sites and acting as a topo II poison to cause DNA strand breaks; it… 
2016
2016
A phase I study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer.
2552 Background: TRC102 (methoxyamine) is a small molecule inhibitor of base-excision repair (BER) that enhances the cytotoxicity… 
2015
2015
Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors
Background: Base excision repair (BER), one of the pathways of DNA damage repair, has been implicated in chemoresistance. TRC102… 
2012
2012
Abstract 1743: Phase 1 clinical trial of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) in combination with Temozolomide (TMZ) in patients with solid tumors
Background: MX is the first base excision repair (BER) inhibitor evaluated in humans. MX blocks the BER pathway by covalently… 
2012
2012
Abstract 753: Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase…
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: MX is the first base excision repair… 
2010
2010
Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.
2576 Background: TRC102 is a small-molecule inhibitor of base-excision repair (BER) that is nearly completely bioavailable after… 
2010
2010
Abstract 682: Dual inhibition of BER by TRC102 and PARP inhibitor (ABT 888) synergistically enhances cytotoxicity of TMZ in human melanoma
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Melanoma, the most fatal skin cancer, has… 
2010
2010
517 Combining pemetrexed with temozolomide and TRC102 (methoxyamine) causes synergistic cytotoxicity in melanoma cells
2009
2009
A PHASE 1 STUDY OF ORAL TRC102 (METHOXYAMINE HYDROCHLORIDE), AN INHIBITOR OF BASE-EXCISION REPAIR, TO POTENTIATE THE THERAPEUTIC EFFECTS OF PEMETREXED IN PATIENTS WITH ADVANCED REFRACTORY CANCER
3 103.0 (93.6 - 239.0) 26.7 (25.4 - 28.0) 1654 (1332 - 4556) 100 mg/m 2 5 225.0 (74.9 - 385.0) 37.0 (25.3 - 45.5) 3697 (940… 
2007
2007
Prevention of base excision repair by TRC102 (methoxyamine) potentiates the anti-tumor activity of pemetrexed in vitro and in vivo
13005 Background: TRC102 (methoxyamine) reverses resistance to alkylating agents by inhibiting base excision repair (BER; a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)